Who is sponsoring NCT02148380?

NCT02148380 is sponsored by Baohui Han.

What condition does NCT02148380 study?

NCT02148380 studies Non-Small-Cell Lung Cancer.

What drugs are being tested in NCT02148380?

Interventions: pemetrexed plus carboplatin, gefitinib.

What is the status of NCT02148380?

NCT02148380 is currently COMPLETED.

Last reviewed 2016-04-19 · How we verify

Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial

NCT02148380 NA COMPLETED

The results of fastact2 show that chemotherapy plus erlotinib significantly prolonged PFS and OS of patients with NSCLC. However, outcome of the combination therapy are similar to those reported in several trials of single-agent EGFR TKIs. So which is the optimal first-line treatment for patients who harbored a sensitive EGFR mutation? The investigators need a head-to-head study to reply.

Details

Lead sponsor	Baohui Han
Phase	NA
Status	COMPLETED
Enrolment	121
Start date	2014-05
Completion	2015-12

Conditions

Non-Small-Cell Lung Cancer

Interventions

pemetrexed plus carboplatin
gefitinib

Primary outcomes

progression-free survival — 6-month

Countries

China